Sarepta Therapeutics to Announce First Quarter 2023 Financial Results

Rhea-AI Summary

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) will release its first quarter 2023 financial results after market close on May 2, 2023. A conference call to discuss these results will be hosted at 4:30 p.m. E.T. The event will be available via webcast on the investor relations section of Sarepta's website.

The company focuses on precision genetic medicine for rare diseases, holding leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs). It boasts a pipeline of over 40 programs in development, driven by its Precision Genetic Medicine Engine employing gene therapy, RNA, and gene editing technologies.

Positive

• Sarepta has a robust pipeline with over 40 programs in various stages of development.
• The company has leadership positions in DMD and LGMDs, which are critical rare diseases.

Negative

• None.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2023 financial results after the Nasdaq Global Market closes on Tuesday, May 2, 2023. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its first quarter 2023 financial results.

The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.

About Sarepta Therapeutics

Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.

Internet Posting of Information

We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230425005062/en/

Investor:

Ian Estepan, 617-274-4052

iestepan@sarepta.com

Media:

Tracy Sorrentino, 617-301-8566

tsorrentino@sarepta.com

Source: Sarepta Therapeutics, Inc.

FAQ

When will Sarepta Therapeutics report its first quarter 2023 financial results?

Sarepta Therapeutics will report its first quarter 2023 financial results after market close on May 2, 2023.

What time is the conference call for Sarepta's Q1 2023 results?

The conference call to discuss Sarepta's Q1 2023 financial results will be held at 4:30 p.m. E.T.

Where can I access Sarepta Therapeutics' financial results webcast?

The webcast for Sarepta's financial results can be found in the investor relations section of its website.

What focus areas does Sarepta Therapeutics specialize in?

Sarepta specializes in precision genetic medicine, particularly in Duchenne muscular dystrophy and limb-girdle muscular dystrophies.